Human embryos erase part of their age-related epigenetic marks around day 7 of development — a real biological phenomenon — and an experimental therapy (ER-100, partial epigenetic reprogramming) has just been cleared by the FDA for a Phase 1 trial, with no human efficacy data yet.

noli's read

The underlying biological fact is real and documented: epigenetic clocks show age gets reset around embryo implantation. ER-100 is a genuine program — Life Biosciences received FDA clearance in January 2026 for a Phase 1 trial (NCT07290244, currently recruiting) delivering three Yamanaka factors (OCT4, SOX2, KLF4) via a viral vector into the eye, for specific conditions (glaucoma, ischemic optic neuropathy) — not a general anti-aging product. This is a Phase 1 safety trial with no published human efficacy data: the leap from the biological mechanism to 'we may soon know if humans can undergo age reversal' is premature. The post faithfully describes a real, verifiable research advance, but the implication of near-term human benefit remains speculative at this stage.

the sources

No named source held this one up — that absence is part of the verdict.